Monday, June 19, 2017
2:00 – 5:00 PM
Albert Einstein College of Medicine
1300 Morris Park Avenue, Bronx, NY
Reception to follow
This kickoff symposium will feature three outstanding and preeminent HIV/AIDS research and treatment leaders as speakers:
“Ending the HIV/AIDS Pandemic: Follow the Science”
Anthony Fauci, MD
Director, National Institute of Allergy and Infectious Diseases
National Institute of Health
“The HIV Vaccine Problem”
Michel C. Nussenzweig, MD, PhD
Head, Laboratory of Molecular Immunology
Investigator, Howard Hughes Medical Institute
Zanvil A. Cohn and Ralph M. Steinman Professor
The Rockefeller University
“Ending the Epidemic: The Art and Science of Reaching Bodies”
Mary T. Bassett, MD, MPH
Commissioner, New York City Department of Health and
The Einstein-Rockefeller-CUNY Center for AIDS Research is driving a clinical implementation and community based research agenda, with resources devoted to behavioral science, clinical translation of research findings into novel treatments, the discovery of biomarkers, applying advanced technologies for improving clinical outcomes and developing an HIV vaccine. Experts in implementation science determine and apply the most effective ways to provide patient care, therapies, testing, and pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) medications to prevent HIV acquisition.
The new center is one of 19 CFARs nationwide that are funded as part of an NIH-coordinated initiative to support multidisciplinary research aimed at reducing the burden of HIV in the United States and abroad. A major focus of the ERC-CFAR’s mission is to translate research into sustainable implementation of population level interventions and strategies that have the potential to improve HIV-related outcomes and reduce health disparities on a large scale.
The ERC-CFAR stimulates, coordinates, and supports an integrated multidisciplinary research agenda to achieve our mission, to arrest the AIDS epidemic, through improving utilization of current treatments and developing new therapies, such as potent broadly neutralizing antibodies, for prevention, reducing the incidence of new infections; treatment, improving treatment outcomes among infected individuals; and eradication of HIV reservoirs.